Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*)

NCT03979508 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03979508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03979508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Terminated
Start date
January 10, 2020
Completion date
December 26, 2024
Enrollment
26 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage i breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, breast ductal carcinoma in situ, breast fibrocystic change, breast lobular carcinoma in situ, invasive breast carcinoma, prognostic stage i breast cancer ajcc v8, prognostic stage ia breast cancer ajcc v8, prognostic stage ib breast cancer ajcc v8, prognostic stage ii breast cancer ajcc v8, prognostic stage iia breast cancer ajcc v8, prognostic stage iib breast cancer ajcc v8, prognostic stage iii breast cancer ajcc v8, prognostic stage iiia breast cancer ajcc v8, prognostic stage iiib breast cancer ajcc v8, prognostic stage iiic breast cancer ajcc v8, triple-negative breast carcinoma